MPS-IH (Hurler Syndrome)

1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Orchard Therapeutics
1 program
1
Experimental: OTL-203Phase 31 trial
Active Trials
NCT06149403Active Not RecruitingEst. Mar 2031

Trial Timeline

Clinical trial activity over time

2023
2024
2025
2026
2027
2028
2029
2030
2031
Orchard TherapeuticsExperimental: OTL-203

Clinical Trials (1)

NCT06149403Orchard TherapeuticsExperimental: OTL-203

A Study to Investigate the Efficacy and Safety of OTL-203 in Subjects With MPS-IH Compared With Standard of Care With Allogeneic HSCT

Start: Dec 2023Est. completion: Mar 2031
Phase 3Active Not Recruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
1 companies competing in this space